Abstract
Objective To use the OpenSAFELY platform to replicate key metrics from a national clinical audit, and assess the impact of COVID-19 on disease incidence and care delivery for inflammatory arthritis (IA) in England.
Design Population-based cohort study, with the approval of NHS England.
Setting Primary care and linked hospital outpatient data for more than 17 million people registered with general practices in England that use TPP electronic health record software.
Participants Adults (18-110 years) with new diagnoses of IA (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, undifferentiated IA) between 1 April 2019 and 31 March 2022.
Main outcome measures The following outcomes were explored before and after April 2020: 1) incidence of IA diagnoses; 2) time from primary care referral to first rheumatology assessment; 3) time to first prescription of a disease-modifying anti-rheumatic drug (DMARD) in primary care.
Results From a reference population of 17,683,500 adults, there were 31,280 incident IA diagnoses between April 2019 and March 2022. The incidence of IA decreased by 20.3% in the year commencing April 2020, relative to the preceding year (5.1 vs. 6.4 diagnoses per 10,000 adults, respectively). For those who presented with IA, the time to first rheumatology assessment was shorter during the pandemic (median 18 days; interquartile range 8 to 35 days) than before (21 days; 9 to 41 days). Overall, the proportion of patients prescribed DMARDs in primary care was comparable during the pandemic to before; however, the choice of medication changed, with fewer people prescribed methotrexate or leflunomide during the pandemic, and more people prescribed sulfasalazine or hydroxychloroquine.
Conclusions The incidence of IA diagnoses in England decreased markedly during the early COVID-19 pandemic. However, for people who sought medical attention, the impact of the pandemic on service delivery was less marked than might have been anticipated. This study demonstrates that it is feasible to use routinely captured, near real-time data in the secure OpenSAFELY platform to benchmark care quality for long-term conditions on a national scale, without the need for manual data collection.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/disclosure-of-interest, and declare: MDR has received honoraria from Lilly and Menarini, support for attending meetings from Lilly, Pfizer, Janssen and UCB, and advisory board fees from Biogen. JG has received honoraria from Abbvie, Biovitrum, BMS, Celgene, Chugai, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, Sobi and UCB. BG has received research funding from the Laura and John Arnold Foundation, NIHR, NIHR School of Primary Care Research, NIHR Oxford Biomedical Research Centre, the Mohn-Westlake Foundation, NIHR Applied Research Collaboration Oxford and Thames Valley, the Wellcome Trust, the Good Thinking Foundation, Health Data Research UK, the Health Foundation, the World Health Organisation, UKRI, Asthma UK, the British Lung Foundation, and the Longitudinal Health and Wellbeing strand of the National Core Studies programme; he also receives personal income from speaking and writing for lay audiences on the misuse of science. A Mahto has received speaker fees from Abbvie and Galapagos, support for attending meetings from Lilly, and has participated in a technology appraisal for Filgotinib. A Mehrkar is a former employee and interim CMO of NHS Digital. APC has received grants from BMS, consulting fees from BMS, Abbvie and GSK/Galvini, speaker fees from BMS and Abbvie, and is on the executive committee of the EULAR research centre. SQ has received grant funding from BMS. JL is clinical director for NEIAA, employed by HQIP via the British Society for Rheumatology for that role, and is a trustee of the British Society for Rheumatology. AIR has support for attending meetings from Lilly. No other authors reported relationships or activities that could appear to have influenced the submitted work.
Funding Statement
KB received funding from Versus Arthritis and Pfizer Global Medical Grants for Quality Improvement in Rheumatology Practice (68033839) to conduct this study. MDR is funded by a National Institute for Health Research (NIHR) Doctoral Fellowship (NIHR300967). The OpenSAFELY data science platform is funded by the Wellcome Trust. BG's work on better use of data in healthcare more broadly is currently funded in part by the Wellcome Trust, NIHR Oxford Biomedical Research Centre, NIHR Applied Research Collaboration Oxford and Thames Valley, the Mohn-Westlake Foundation; all DataLab staff are supported by BG's grants on this work. BMK is also employed by NHS England, working on medicines policy, and is clinical lead for primary care medicines data. The views expressed in this publication are those of the authors and not necessarily those of the NHS, NIHR, Public Health England, or the Department of Health and Social Care. The funder had no role in study design, data collection, analysis or interpretation, manuscript writing, or in the decision to submit the article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval to undertake this study under the remit of service evaluation was obtained from Kings College Hospital NHS Foundation Trust. No further ethical approval was required as per UK Health Research Authority guidance.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint first authorsh
james.galloway{at}kcl.ac.uk
colm.andrews{at}phc.ox.ac.uk
brian.mackenna{at}nhs.net
ben.goldacre{at}phc.ox.ac.uk
amir.mehrkar{at}phc.ox.ac.uk
helen.curtis{at}phc.ox.ac.uk
benjamin.butler-cole{at}phc.ox.ac.uk
thomas.odwyer{at}phc.ox.ac.uk
sumera.qureshi{at}kcl.ac.uk
jo.ledingham{at}porthosp.nhs.uk
arti.mahto{at}nhs.net
arutherford1{at}nhs.net
maryam.adas{at}kcl.ac.uk
edward.alveyn{at}nhs.net
sam.norton{at}kcl.ac.uk
andrew.cope{at}kcl.ac.uk
katie.bechman{at}kcl.ac.uk
Data Availability
Access to the underlying identifiable and potentially re-identifiable pseudonymised electronic health record data is tightly governed by various legislative and regulatory frameworks, and restricted by best practice. The data in OpenSAFELY is drawn from General Practice data across England where TPP is the Data Processor. TPP developers (Chris Bates, Jonathan Cockburn, John Parry, Frank Hester, and Sam Harper) initiate an automated process to create pseudonymised records in the core OpenSAFELY database, which are copies of key structured data tables in the identifiable records. These are linked onto key external data resources that have also been pseudonymised via SHA-512 one-way hashing of NHS numbers using a shared salt. DataLab developers and PIs (Ben Goldacre, Liam Smeeth, Caroline E Morton, Seb Bacon, Alex J Walker, William Hulme, Helen J Curtis, David Evans, Peter Inglesby, Simon Davy, George Hickman, Krishnan Bhaskaran and Christopher T Rentsch) holding contracts with NHS England have access to the OpenSAFELY pseudonymised data tables as needed to develop the OpenSAFELY tools. These tools in turn enable researchers with OpenSAFELY Data Access Agreements to write and execute code for data management and data analysis without direct access to the underlying raw pseudonymised patient data, and to review the outputs of this code. All code for the full data management pipeline, from raw data to completed results for this analysis, and for the OpenSAFELY platform as a whole is available for review at github.com/OpenSAFELY. The data management and analysis code for this paper was led by MDR and JBG.